The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Kura Oncology Inc (NASDAQ: KURA) was $7.99 for the day, down -3.56% from the previous closing price of $8.28. In other words, the price has decreased by -$3.56 from its previous closing price. On the day, 0.9 million shares were traded.
Ratios:
Our analysis of KURA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 11.47 and its Current Ratio is at 11.47. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
On October 24, 2024, UBS started tracking the stock assigning a Buy rating and target price of $27.
Stifel Downgraded its Buy to Hold on October 14, 2024, whereas the target price for the stock was revised from $26 to $19.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 28 ’25 when DOYLE THOMAS JAMES sold 4,949 shares for $7.87 per share. The transaction valued at 38,958 led to the insider holds 88,193 shares of the business.
Leoni Mollie sold 4,963 shares of KURA for $39,068 on Jan 28 ’25. The Chief Medical Officer now owns 88,253 shares after completing the transaction at $7.87 per share. On Jan 28 ’25, another insider, Bair Teresa Brophy, who serves as the Chief Legal Officer of the company, sold 7,281 shares for $7.87 each. As a result, the insider received 57,315 and left with 107,948 shares of the company.
Stock Price History:
Over the past 52 weeks, KURA has reached a high of $24.17, while it has fallen to a 52-week low of $6.98. The 50-Day Moving Average of the stock is -7.57%, while the 200-Day Moving Average is calculated to be -52.09%.
Shares Statistics:
A total of 77.75M shares are outstanding, with a floating share count of 71.35M. Insiders hold about 8.24% of the company’s shares, while institutions hold 99.81% stake in the company.
Earnings Estimates
The stock of Kura Oncology Inc (KURA) is currently drawing attention from 10.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.51, with high estimates of $0.15 and low estimates of -$0.71.
Analysts are recommending an EPS of between -$2.1 and -$2.56 for the fiscal current year, implying an average EPS of -$2.41. EPS for the following year is -$1.9, with 10.0 analysts recommending between $0.15 and -$3.05.
